Eyeing big returns, drugmakers ready new hepatitis-C drug launches
The FDA also last week approved Daklinza (daclatasvir), a treatment developed by Bristol-Myers Squibb to treat genotype-3 infections in combination with Sovaldi. It does not require the co-administration of interferon or ribavirin.
The FDA also last week approved Daklinza (daclatasvir), a treatment developed by Bristol-Myers Squibb to treat genotype-3 infections in combination with Sovaldi. It does not require the co-administration of interferon or ribavirin.